Amy Roshak
Amy Roshak publishes mostly in Pulmonary and Respiratory Medicine, Molecular Biology and Oncology, on topics such as Lung Cancer Treatments and Mutations, Protein Kinase Regulation and GTPase Signaling and Inflammatory mediators and NSAID effects.
- World rank
- #708,775 of 7,710,434 ranked researchers
- Rank in United States
- #239,385 of 1,627,098
- Works
- 47
- Citations
- 3.9k
- Citations per work
- 82.7
What does Amy Roshak research?
Amy Roshak's work is mostly in Medicine (40%), Biochemistry, Genetics and Molecular Biology (22%), Immunology and Microbiology (6%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1940.5%
- Medicine1940.5%
- Everything else1531.2%
- Life Sciences1328.3%
- 1Pulmonary and Respiratory Medicine21% of their works
- 2Molecular Biology14% of their works
- 3Oncology12% of their works
- 4Cancer Research8% of their works
- 5Pharmacology7% of their works
- 6Immunology6% of their works
Research topics
- Lung Cancer Treatments and Mutations
- Protein Kinase Regulation and GTPase Signaling
- Inflammatory mediators and NSAID effects
- Lung Cancer Diagnosis and Treatment
- NF-κB Signaling Pathways
- Colorectal Cancer Treatments and Studies
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Lung Cancer Research Studies
Which keywords describe Amy Roshak's research?
The keywords of their largest research topics: Clinical Trials, Targeted Therapy, ALK Inhibitors, EGFR Mutations, Chemotherapy, Inflammation, Cancer and Immunity.
- Small-Cell Lung Cancer
- Neutrophil Extracellular Traps
- Signaling
- KRAS Mutations
- Ras Signaling
- Prostaglandins
- Cyclooxygenase-2 Inhibitors
- Immunity
- Inflammation
- EGFR Mutations
- Targeted Therapy
- Clinical Trials
- ALK Inhibitors
- Chemotherapy
- Cancer
- CT Screening
- Lung Cancer
- Protein Kinases
- Cetuximab
- NF-?B
- Genomic Profiles
- Reactive Oxygen Species
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 22 words, with their numbers
- Clinical Trials222 topics
- Targeted Therapy222 topics
- ALK Inhibitors181 topic
- EGFR Mutations181 topic
- Chemotherapy163 topics
- Inflammation163 topics
- Cancer122 topics
- Immunity92 topics
- CT Screening71 topic
- Cyclooxygenase-2 Inhibitors71 topic
- Lung Cancer71 topic
- Prostaglandins71 topic
- Protein Kinases71 topic
- Ras Signaling71 topic
- Cetuximab51 topic
- KRAS Mutations51 topic
- NF-?B51 topic
- Signaling51 topic
- Genomic Profiles41 topic
- Neutrophil Extracellular Traps41 topic
- Reactive Oxygen Species41 topic
- Small-Cell Lung Cancer41 topic
Where does Amy Roshak work?
Amy Roshak's main affiliation in the publication record is New Frontier, United States.
How many publications and citations does Amy Roshak have?
OpenAlex counts 47 works and 3,889 citations for Amy Roshak, an h-index of 29, ranking #708,775 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Amy Roshak. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.